{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:49:27Z","timestamp":1790786967036,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T00:00:00Z","timestamp":1570320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Ministry of Education","award":["NRF-2017R1D1A1B03034639"],"award-info":[{"award-number":["NRF-2017R1D1A1B03034639"]}]},{"name":"The Ministry of Health &amp; Welfare","award":["HI16C2037"],"award-info":[{"award-number":["HI16C2037"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The established biomarker for hepatocellular carcinoma (HCC), serum \u03b1-fetoprotein (AFP), has suboptimal performance in early disease stages. This study aimed to develop a metabolite panel to differentiate early-stage HCC from cirrhosis. Cross-sectional metabolomic analyses of serum samples were performed for 53 and 47 patients with early HCC and cirrhosis, respectively, and 50 matched healthy controls. Results were validated in 82 and 80 patients with early HCC and cirrhosis, respectively. To retain a broad spectrum of metabolites, technically distinct analyses (global metabolomic profiling using gas chromatography time-of-flight mass spectrometry and targeted analyses using liquid chromatography with tandem mass spectrometry) were employed. Multivariate analyses classified distinct metabolites; logistic regression was employed to construct a prediction model for HCC diagnosis. Five metabolites (methionine, proline, ornithine, pimelylcarnitine, and octanoylcarnitine) were selected in a panel. The panel distinguished HCC from cirrhosis and normal controls, with an area under the receiver operating curve (AUC) of 0.82; this was significantly better than that of AFP (AUC: 0.75). During validation, the panel demonstrated significantly better predictability (AUC: 0.94) than did AFP (AUC: 0.78). Defects in ammonia recycling, the urea cycle, and amino acid metabolism, demonstrated on enrichment pathway analysis, may reliably distinguish HCC from cirrhosis. Compared with AFP alone, the metabolite panel substantially improved early-stage HCC detection.<\/jats:p>","DOI":"10.3390\/cancers11101497","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T03:34:01Z","timestamp":1570419241000},"page":"1497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-6029","authenticated-orcid":false,"given":"Da","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2677-3189","authenticated-orcid":false,"given":"Eun","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-590X","authenticated-orcid":false,"given":"Taesung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Statistics, Seoul National University, Seoul 08826, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8273","authenticated-orcid":false,"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Singal, A.G., Pillai, A., and Tiro, J. (2014). Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: A meta-analysis. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001624"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"European Association For the Study of the Liver, and European Organisation for Research and Treatment of Cancer (2012). EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. Eur. J. Cancer, 48, 599\u2013641.","DOI":"10.1016\/j.ejca.2011.12.021"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrm.2016.25","article-title":"Metabolomics: Beyond biomarkers and towards mechanisms","volume":"17","author":"Johnson","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/liv.12541","article-title":"Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC\/MS and UPLC\/MS-MS","volume":"34","author":"Fitian","year":"2014","journal-title":"Liver Int."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nezami Ranjbar, M.R., Luo, Y., Di Poto, C., Varghese, R.S., Ferrarini, A., Zhang, C., Sarhan, N.I., Soliman, H., Tadesse, M.G., and Ziada, D.H. (2015). GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127299"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/acn3.726","article-title":"A metabolomic approach to identifying biomarkers in blood of Alzheimer\u2019s disease","volume":"6","author":"Lin","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Varma, V.R., Oommen, A.M., Varma, S., Casanova, R., An, Y., Andrews, R.M., O\u2019Brien, R., Pletnikova, O., Troncoso, J.C., and Toledo, J. (2018). Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002482"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Balashova, E.E., Maslov, D.L., and Lokhov, P.G. (2018). A Metabolomics Approach to Pharmacotherapy Personalization. J. Pers. Med., 8.","DOI":"10.3390\/jpm8030028"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hep.29561","article-title":"A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma","volume":"67","author":"Luo","year":"2018","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/JHC.S159808","article-title":"Hepatocellular carcinoma: A review of diagnostic challenges for the pathologist","volume":"5","author":"Quaglia","year":"2018","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: A review","volume":"3","author":"Balogh","year":"2016","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.pai.0000213105.18569.fa","article-title":"Geometry of human vascular system: Is it an obstacle for quantifying antiangiogenic therapies?","volume":"15","author":"Grizzi","year":"2007","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: Incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4254\/wjh.v7.i2.139","article-title":"Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis","volume":"7","author":"Schutte","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_17","first-page":"410","article-title":"Novel biomarkers for hepatocellular carcinoma surveillance: Has the future arrived?","volume":"3","author":"Gonzalez","year":"2014","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbrc.2003.11.023","article-title":"Pharmacological activities of branched-chain amino acids: Specificity of tissue and signal transduction","volume":"313","author":"Nishitani","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.3748\/wjg.v19.i43.7620","article-title":"Branched-chain amino acids in liver diseases","volume":"19","author":"Tajiri","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/tgh.2018.07.06","article-title":"Branched-chain amino acids in liver diseases","volume":"3","author":"Tajiri","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.bbrc.2003.11.039","article-title":"Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes","volume":"312","author":"Doi","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1096\/fj.03-1409fje","article-title":"Amino acids and leucine allow insulin activation of the PKB\/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db\/db mice","volume":"18","author":"Hinault","year":"2004","journal-title":"FASEB J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrendo.2014.171","article-title":"Branched-chain amino acids in metabolic signalling and insulin resistance","volume":"10","author":"Lynch","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.freeradbiomed.2017.01.009","article-title":"High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation","volume":"104","author":"Zhenyukh","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12986-018-0271-1","article-title":"Branched-chain amino acids in health and disease: Metabolism, alterations in blood plasma, and as supplements","volume":"15","author":"Holecek","year":"2018","journal-title":"Nutr. Metab. (Lond.)"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/bmb.2003.494031050249","article-title":"The urea cycle: Teaching intermediary metabolism in a physiological setting","volume":"31","author":"Watford","year":"2003","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1126\/science.aam9305","article-title":"Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass","volume":"358","author":"Spinelli","year":"2017","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"857S","DOI":"10.3945\/ajcn.2009.27462Z","article-title":"Hepatic glutamate metabolism: A tale of 2 hepatocytes","volume":"90","author":"Brosnan","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41568-018-0054-z","article-title":"Rewiring urea cycle metabolism in cancer to support anabolism","volume":"18","author":"Keshet","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev.nutr.22.110801.140547","article-title":"Regulation of enzymes of the urea cycle and arginine metabolism","volume":"22","author":"Morris","year":"2002","journal-title":"Annu. Rev. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0168-8278(00)80122-1","article-title":"Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma","volume":"33","author":"Avila","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0005-2760(93)90161-2","article-title":"Acylcarnitine formation and fatty acid oxidation in hepatocytes from rats treated with tetradecylthioacetic acid (a 3-thia fatty acid)","volume":"1167","author":"Skrede","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Li, S., Gao, D., and Jiang, Y. (2019). Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma. Metabolites, 9.","DOI":"10.3390\/metabo9020036"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mc.22967","article-title":"Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2","volume":"58","author":"Lu","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1038\/s41598-019-47216-2","article-title":"Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma","volume":"9","author":"Enooku","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: A prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11306-019-1494-5","article-title":"Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways","volume":"15","author":"Kim","year":"2019","journal-title":"Metabolomics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11874","DOI":"10.1038\/s41598-018-30349-1","article-title":"Ursodeoxycholic acid improves liver function via phenylalanine\/tyrosine pathway and microbiome remodelling in patients with liver dysfunction","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/10\/1497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:27:55Z","timestamp":1760189275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/10\/1497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,6]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["cancers11101497"],"URL":"https:\/\/doi.org\/10.3390\/cancers11101497","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,6]]}}}